The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts with a total potential value of $364,553,934 to support preclinical and translational vaccine development services. Task areas under the contracts include product storage and shipping, safety and immunogenicity studies, feasibility assessments, analytical development, process development, cGMP manufacturing, stability testing, fill-finish, and scientific/quality support. Task Area G for scientific, quality, and regulatory support services is set aside for small businesses.
One of the task orders awarded was a $3,542,296 cost-plus-fixed-fee order to Mriglobal, doing business in Kansas City, Missouri, for research and development product storage and shipping from December 2021 through November 2028. The order aims to provide logistics and storage support for preclinical and translational vaccine development for HIV and other candidate agents. Performance will take place in Kansas City, Missouri through November 2028. Subcontracting was also authorized.
The purpose of the contracts is to support the National Institute of Allergy and Infectious Diseases' goal of developing a safe and effective HIV vaccine through preclinical and translational research services, from initial discovery through clinical trials and licensure. The multiple award structure aims to provide flexible support across the product development continuum.
Generated 1/4/24, 9:29 PM